Immediate Impact

2 from Science/Nature 63 standout
Sub-graph 1 of 21

Citing Papers

Multi drug resistance in Colorectal Cancer- approaches to overcome, advancements and future success
2024 Standout
Colorectal cancer
2024 Standout
3 intermediate papers

Works of Usman Shah being referenced

Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Two-year clinical update.
2020
Nivolumab (NIVO) + low-dose ipilimumab (IPI) as first-line (1L) therapy in microsatellite instability-high/DNA mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Clinical update.
2019
and 2 more

Author Peers

Author Last Decade Papers Cites
Usman Shah 66 214 111 92 32 397
Haixia Jia 51 146 65 75 30 397
Jia Zhu 54 118 60 59 64 382
Shu‐Yun Ma 34 149 113 44 43 428
Han Liu 81 83 29 53 38 385
Yajin Chen 124 131 72 104 22 420
Jia-Bin Liao 14 72 61 69 29 359
Linrong Li 14 148 118 58 29 452
Chong Zhang 89 129 28 61 26 445
Weiluo Cai 39 111 32 103 22 386
Kui Meng 73 60 36 62 29 416

All Works

Loading papers...

Rankless by CCL
2026